The Integrative Health Podcast with Dr. Jen

Episode #21 The Mirena and Leaky Vaginas with Dr. Felice Gersh

May 25, 2021 Dr. Jen
Episode #21 The Mirena and Leaky Vaginas with Dr. Felice Gersh
The Integrative Health Podcast with Dr. Jen
More Info
The Integrative Health Podcast with Dr. Jen
Episode #21 The Mirena and Leaky Vaginas with Dr. Felice Gersh
May 25, 2021
Dr. Jen

Dr. Felice Gersh
Website: www.integrativemgi.com

Practice:

Integrative Medical Group of
 Irvine

Irvine, California 92604

Social Media:

Instagram  @dr.felicegersh
https://www.instagram.com/dr.felicegersh/

Twitter  @DrFeliceGersh
https://twitter.com/DrFeliceGersh

Facebook  @felicegershmd
https://www.facebook.com/felicegershmd/

Youtube Channel:

https://www.youtube.com/channel/UCrbn9RUdGuc6Wq-FT7V4u3g

Studies:
https://pubmed.ncbi.nlm.nih.gov/26243443/ 
Levonorgestrel-releasing intrauterine system and the risk of breast cancer: A nationwide cohort study

Conclusions: The results imply that intrauterine administration of levonorgestrel is not only related to an excess risk of lobular breast cancer but also, in contrary to previous assumptions, to an excess risk of ductal breast cancer.

Impact of levonorgestrel-releasing intrauterine system use on the cancer risk of the ovary and fallopian tube

Conclusions: LNG-IUS use associated with decreased risk for both invasive and borderline ovarian tumors. The incidence of primary fallopian tube 

https://pubmed.ncbi.nlm.nih.gov/27148621/

Levonorgestrel-releasing intrauterine system and breast cancer risk: A systematic review and meta-analysis
Conclusions: Current evidence suggests that LNG-IUS users have an increased breast cancer risk regardless of age and indication. The effect of LNG-IUS on breast cancer risk seems to be larger in older users. However, our systematic review detected methodological issues across the available studies, and confounding factors may be responsible for at least a fraction of the risk effects associated with LNG-IUS use. Nevertheless, users of LNG-IUS should be aware of these trends. We believe that caution is needed, and risks should be balanced against proven health benefits (eg effective treatment of heavy menstrual bleeding and avoidance of surgical interventions), when prescribing LNG-IUS for long periods of use, especially in women with other known breast cancer risk factors such as old age, obesity, and familial predisposition

https://pubmed.ncbi.nlm.nih.gov/31990981/

Thank you for listening!
Please comment on future topics and questions you would like for the Podcast!

Show Notes

Dr. Felice Gersh
Website: www.integrativemgi.com

Practice:

Integrative Medical Group of
 Irvine

Irvine, California 92604

Social Media:

Instagram  @dr.felicegersh
https://www.instagram.com/dr.felicegersh/

Twitter  @DrFeliceGersh
https://twitter.com/DrFeliceGersh

Facebook  @felicegershmd
https://www.facebook.com/felicegershmd/

Youtube Channel:

https://www.youtube.com/channel/UCrbn9RUdGuc6Wq-FT7V4u3g

Studies:
https://pubmed.ncbi.nlm.nih.gov/26243443/ 
Levonorgestrel-releasing intrauterine system and the risk of breast cancer: A nationwide cohort study

Conclusions: The results imply that intrauterine administration of levonorgestrel is not only related to an excess risk of lobular breast cancer but also, in contrary to previous assumptions, to an excess risk of ductal breast cancer.

Impact of levonorgestrel-releasing intrauterine system use on the cancer risk of the ovary and fallopian tube

Conclusions: LNG-IUS use associated with decreased risk for both invasive and borderline ovarian tumors. The incidence of primary fallopian tube 

https://pubmed.ncbi.nlm.nih.gov/27148621/

Levonorgestrel-releasing intrauterine system and breast cancer risk: A systematic review and meta-analysis
Conclusions: Current evidence suggests that LNG-IUS users have an increased breast cancer risk regardless of age and indication. The effect of LNG-IUS on breast cancer risk seems to be larger in older users. However, our systematic review detected methodological issues across the available studies, and confounding factors may be responsible for at least a fraction of the risk effects associated with LNG-IUS use. Nevertheless, users of LNG-IUS should be aware of these trends. We believe that caution is needed, and risks should be balanced against proven health benefits (eg effective treatment of heavy menstrual bleeding and avoidance of surgical interventions), when prescribing LNG-IUS for long periods of use, especially in women with other known breast cancer risk factors such as old age, obesity, and familial predisposition

https://pubmed.ncbi.nlm.nih.gov/31990981/

Thank you for listening!
Please comment on future topics and questions you would like for the Podcast!